Hemoglobinopathies Market to Grow with a CAGR of 12.59% through 2029

Increase in the global disease burden and increase in the newborn screening programs is expected to drive the Global Hemoglobinopathies Market growth in the forecast period.

According to TechSci Research report, “Hemoglobinopathies Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the Global Hemoglobinopathies Market stood at USD 8.30 billion in 2023 and is anticipated to grow with a CAGR of 12.59% in the forecast period, 2025-2029. The awareness among individuals regarding Hemoglobinopathies has led to favorable market conditions for the global Hemoglobinopathies market. Several factors contribute to the growth of various Hemoglobinopathies products. The growth of the hemoglobinopathies market has been notably propelled by the development and adoption of cutting-edge diagnostic technologies. The increasing collaborative initiatives between governmnet agenices, not-for-profit organizations, and private sector are driving research funding, infrastructural development, and access to care for individuals suffering from hemoglobinopathies, thereby supporting the global hemoglobinopathies market growth. 

The growing healthcare infrastructure and rising healthcare expenditures in emerging economies is contributing access to diagnosis and treatment of diseases thereby creating opportunities for the growth of hemoglobinopathies market as well. Also, regulatory agencies are recognizing the unmet medical needs in hemoglobinopathies and are providing expedited pathways and incentives to facilitate the development of innovative therapies. 

However, Hemoglobinopathies, including sickle cell disease and thalassemia, result from genetic mutations, making them inherently complex to treat. Historically, treatment options for hemoglobinopathies have been limited, with symptomatic management and blood transfusions being primary approaches.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Hemoglobinopathies Market”

The Global Hemoglobinopathies Market is segmented into type, diagnosis, therapy, regional distribution, and company

Based on its type, the Sickle Cell Disease segment emerged as the dominant segment in the global market for Hemoglobinopathies in 2023. The market's growth can be attributed to the increased efforts of biopharmaceutical companies and nonprofit organizations dedicated to enhancing access to sickle cell disease (SCD) treatment. While thalassemia segment is expected to witness substantial growth owing to increasing disease prevalence both among the newborns and the adults. 

Based on region, North America segment is expected to grow during the forecast period. The growth of the hemoglobinopathies market in the region is driven by well established healthcare infrastructure in the region which supports early diagnosis and treatment of hemoglobinopathies. Healthcare system in countries like United States and Canada provide comprehensive care and care for individuals living with hemoglobinopathies. This includes access to specialized medical centers, hematologists, genetic counselors, etc. 

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Hemoglobinopathies players during the forecast period. Asia Pacific is home to diverse pool of population with varying genetic profiles, leading to wide range in the prevalence of hemoglobinopathies across different countries. For instance, countries like India, Pakistan, Bangladesh and South-East Asian countries have relatively high prevalence of thalassemia. 

Major companies operating in Global Hemoglobinopathies Market are:

• Sangamo Therapeutics, Inc.
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi S.A. (Bioverativ Inc.)
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Advancements in Diagnostic Technologies and increasing in the development and approval of novel therapies are key drivers of the Hemoglobinopathies market. In recent years, the growing global prevalence and awareness of hemoglobinopathies prompt healthcare organizations and governments to invest in improved patient care and expand access to treatment and support services. Moreover, the growing consumer emphasis on preventative healthcare has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Hemoglobinopathies market in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Hemoglobinopathies Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others), By Therapy (Blood Transfusion, Iron Chelation Therapy, Hydroxyurea, Bone Marrow Transplant, Others), By Region, Competition 2019-2029F”, has evaluated the future growth potential of Global Hemoglobinopathies Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Hemoglobinopathies Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com